| Janssen-Cilag AG - Darzalex 100mg/5ml, Konzentrat zur Herstellung einer Infusionslösung |
| 66072 | | 03 | | Darzalex 100mg/5ml | | Konzentrat zur Herstellung einer Infusionslösung | | L01FC01 | | | | 27.01.2023 | | |
|
| Composition |
| daratumumabum 100 mg, histidinum, histidini hydrochloridum monohydricum, sorbitolum 273.3 mg, methioninum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 5 ml. |
| Packungsbestandteile |
| Concentrate for infusion | | | | | | | | Active Agent | Dose |
|---|
| Daratumumabum | 100mg / 5ml |
| | BAG: Active Agent | Dose |
|---|
| Daratumumabum | 100 mg |
| | | | Inactive agents | Dose |
|---|
| Histidin Hydrochloride Monohydrate | | | Histidine | | | Methionine | | | Polysorbatum 20 | | | Sorbitol | 273.3mg / 5ml |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 003 | | 404.57 | 456.40 | A | SL | Yes |
|
